Prostate RAD-ONC Study

The purpose of this study is to test the safety of a new type of IG-IMRT called "ultra-hypofractionated IG-IMRT" where a higher dose of radiation is given to the tumor during each treatment day. Since higher doses of radiation are used each day, the total number of treatment days needed to complete this type of radiation is only five instead of the 45-48 treatments currently used. Treatment takes place every other day and is complete after 2 weeks. If the patient decides to get this treatment, they will come in for 5 treatments. This is different from the 48 treatments they would get normally.

Eligibility Criteria:

1. Eligibility is not restricted to MSKCC to confirm biopsy/diagnosis. Participating institution testing is sufficient.
2. Low and intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines.
3. Low risk patients will be defined as:

1. PSA < or = to 10 ng/ml and
2. Gleason score = 6 and
3. Clinical Stage < or = to T2a

         Intermediate risk patients will be defined as:

1. PSA 10-20 ng/ml or
2. Gleason score = 7 or
3. Clinical stage T2b/T2c

This study is for patients age 18 and older.

Available at: Hartford Hospital, Hospital of Central Connecticut